Cannabidiol Oral Solution [Epidiolex]

DRUG2 trials

Sponsors

Silkiss Eye Surgery, Jazz Pharmaceuticals

Conditions

BlepharospasmBlepharospasm, Benign EssentialCBDTuberous Sclerosis Complex Associated Neuropsychiatric Disease

Phase 2

Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm

CompletedNCT04423341

Silkiss Eye SurgeryBlepharospasm, Blepharospasm, Benign Essential, CBD

Start: 2020-05-20End: 2021-10-01Updated: 2021-11-02

Phase 4

A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

CompletedNCT05864846

Jazz PharmaceuticalsTuberous Sclerosis Complex Associated Neuropsychiatric Disease

Start: 2023-06-29End: 2026-04-06Updated: 2026-04-27

Related Papers

Co-Creation of the EpiCom Clinical Trial: Bringing the Tuberous Sclerosis Complex Patient Community, Healthcare Professionals, and the Pharmaceutical Industry Together

Patient2026-07-11

Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)

PLoS ONE2025-06-12

SPIRIT checklist.

OPAL (Open@LaTrobe) (La Trobe University)2025-06-12